Curanex Pharmaceuticals’ (NASDAQ:CURX – Get Free Report) quiet period will end on Monday, October 6th. Curanex Pharmaceuticals had issued 3,750,000 shares in its initial public offering on August 26th. The total size of the offering was $15,000,000 based on an initial share price of $4.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Analysts Set New Price Targets
Separately, Wall Street Zen raised shares of Curanex Pharmaceuticals to a “hold” rating in a report on Saturday, August 30th.
View Our Latest Stock Report on Curanex Pharmaceuticals
Curanex Pharmaceuticals Price Performance
Curanex Pharmaceuticals Company Profile
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances.
Featured Stories
- Five stocks we like better than Curanex Pharmaceuticals
- What is the Euro STOXX 50 Index?
- Why the Precious Metal Nobody Talks About Could Be Your Best Bet
- Investing in the High PE Growth Stocks
- Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
- There Are Different Types of Stock To Invest In
- 3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Receive News & Ratings for Curanex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curanex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.